NEW YORK (GenomeWeb) — Highmark Health announced today that it will study the clinical and economic impact of Biocept's Target Selector liquid biopsy in patients with non-small cell lung cancer.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.